{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:57:28Z","timestamp":1774976248096,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Philips\/InnoSIGN"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02245-4","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:55:41Z","timestamp":1772031341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pathway activity profiling can predict neoadjuvant endocrine therapy response in HR+ HER2- postmenopausal early stage breast cancer"],"prefix":"10.1186","volume":"28","author":[{"given":"N.","family":"de Gruil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. F.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Wesseling-Rozendaal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Keizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.S.","family":"Koekenbier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Vermeer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. B.","family":"Heijns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. M. P. W.","family":"Mandigers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"van de Wouw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cloos-van Balen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Ropela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. M.","family":"Oosterkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. L.","family":"van Bekkum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Houtsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. den","family":"Biezen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. J.","family":"Liefers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. C.","family":"Linn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. R.","family":"Kroep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"1","key":"2245_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1023\/a:1020299707510","volume":"76","author":"WF Anderson","year":"2002","unstructured":"Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat. 2002;76(1):27\u201336. https:\/\/doi.org\/10.1023\/a:1020299707510","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"2245_CR2","doi-asserted-by":"publisher","first-page":"6834","DOI":"10.3390\/ijms24076834","volume":"24","author":"L Clusan","year":"2023","unstructured":"Clusan L, Ferri\u00e8re F, Flouriot G, Pakdel F. A basic review on estrogen receptor signaling pathways in breast cancer. Int J Mol Sci. 2023;24(7):6834. https:\/\/doi.org\/10.3390\/ijms24076834.","journal-title":"Int J Mol Sci"},{"key":"2245_CR3","doi-asserted-by":"publisher","first-page":"102669","DOI":"10.1016\/j.ctrv.2023.102669","volume":"123","author":"L Cantini","year":"2024","unstructured":"Cantini L, Cortesi L, Lambertini M, Di Leo A. Neoadjuvant therapy in hormone receptor-positive\/HER2-negative breast cancer. Cancer Treat Rev. 2024;123:102669. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102669.","journal-title":"Cancer Treat Rev"},{"key":"2245_CR4","doi-asserted-by":"publisher","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","DOI":"10.1016\/j.cell.2011.02.013"},{"issue":"11","key":"2245_CR5","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1158\/0008-5472.CAN-13-2515","volume":"74","author":"W Verhaegh","year":"2014","unstructured":"Verhaegh W, van Ooijen H, Inda MA, Hatzis P, Versteeg R, Smid M, et al. Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways. Cancer Res. 2014;74(11):2936\u201345. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2515.","journal-title":"Cancer Res"},{"issue":"2","key":"2245_CR6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1535-7163.MCT-19-0318","volume":"19","author":"MA Inda","year":"2020","unstructured":"Inda MA, Blok EJ, Kuppen PJK, Charehbili A, den Biezen-Timmermans EC, van Brussel A, et al. Estrogen receptor pathway activity score to predict clinical response or resistance to neoadjuvant endocrine therapy in primary breast cancer. Mol Cancer Ther. 2020;19(2):680\u20139. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0318.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2245_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","volume":"144","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists guideline update. Arch Pathol Lab Med. 2020;144(5):545\u201363. https:\/\/doi.org\/10.5858\/arpa.2019-0904-SA.","journal-title":"Arch Pathol Lab Med"},{"issue":"19","key":"2245_CR8","doi-asserted-by":"publisher","first-page":"5687","DOI":"10.1158\/1078-0432.CCR-17-0900","volume":"23","author":"CX Ma","year":"2017","unstructured":"Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, et al. Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplified metastatic breast cancer. Clin Cancer Res. 2017;23(19):5687\u201395. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0900.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2245_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1158\/1078-0432.CCR-11-1236","volume":"18","author":"AW Welsh","year":"2012","unstructured":"Welsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, et al. Cytoplasmic estrogen receptor in breast cancer. Clin Cancer Res. 2012;18(1):118\u201326. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1236.","journal-title":"Clin Cancer Res"},{"key":"2245_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-020-0146-2","volume":"6","author":"D Caruana","year":"2020","unstructured":"Caruana D, Wei W, Martinez-Morilla S, et al. Association between low estrogen receptor-positive breast cancer and staining performance. npj Breast Cancer. 2020;6:5. https:\/\/doi.org\/10.1038\/s41523-020-0146-2.","journal-title":"npj Breast Cancer"},{"issue":"2","key":"2245_CR11","first-page":"155","volume":"11","author":"DC Allred","year":"1998","unstructured":"Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155\u201368.","journal-title":"Mod Pathol"},{"issue":"8 Suppl","key":"2245_CR12","first-page":"s4244","volume":"46","author":"KS McCarty Jr","year":"1986","unstructured":"McCarty KS Jr, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 1986;46(8 Suppl):s4244\u20138.","journal-title":"Cancer Res"},{"key":"2245_CR13","doi-asserted-by":"publisher","first-page":"117822341982907","DOI":"10.1177\/1178223419829072","volume":"13","author":"C Selli","year":"2019","unstructured":"Selli C, Sims AH. Neoadjuvant therapy for breast cancer as a model for translational research. Breast Cancer. 2019;13:1178223419829072. https:\/\/doi.org\/10.1177\/1178223419829072.","journal-title":"Breast Cancer (Auckl)"},{"key":"2245_CR14","doi-asserted-by":"publisher","unstructured":"Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer: an overview and update. Mol Cell Endocrinol. 2015;418(Pt 3):220\u201334. https:\/\/doi.org\/10.1016\/j.mce.2015.09.035.","DOI":"10.1016\/j.mce.2015.09.035"},{"issue":"19","key":"2245_CR15","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/jnci\/djn309","volume":"100","author":"MJ Ellis","year":"2008","unstructured":"Ellis MJ, Tao Y, Luo J, A\u2019Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100(19):1380\u20138. https:\/\/doi.org\/10.1093\/jnci\/djn309.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2245_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.37349\/etat.2021.00052","volume":"2","author":"KA Altwegg","year":"2021","unstructured":"Altwegg KA, Vadlamudi RK. Role of estrogen receptor coregulators in endocrine-resistant breast cancer. Explor Target Antitumor Ther. 2021;2(4):385\u2013400. https:\/\/doi.org\/10.37349\/etat.2021.00052.","journal-title":"Explor Target Antitumor Ther"},{"key":"2245_CR17","doi-asserted-by":"publisher","unstructured":"de Groot AF, Cohen D, Heijns JB, Mandigers CMPW, van de Wouw AJ, Cloos-van Balen M, Ropela JA, Oosterkamp HM, van Bekkum ML, Houtsma D, Putter H, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Dijkstra KL, van Leeuwen-Stok AE, van der Burg SH, Liefers GJ, Linn SC, Kroep JR. Ribociclib-letrozole combination as an alternative for neoadjuvant chemotherapy in selected post-menopausal patients with luminal breast cancer (BOOG 2017-01). Clin Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3402.","DOI":"10.1158\/1078-0432.CCR-24-3402"},{"key":"2245_CR18","doi-asserted-by":"publisher","first-page":"598118","DOI":"10.3389\/fgene.2020.598118","volume":"11","author":"A van de Stolpe","year":"2021","unstructured":"van de Stolpe A, Verhaegh W, Blay JY, Ma CX, Pauwels P, Pegram M, et al. RNA-based approaches to profile oncogenic pathways from low-quantity samples to drive precision oncology strategies. Front Genet. 2021;11:598118. https:\/\/doi.org\/10.3389\/fgene.2020.598118.","journal-title":"Front Genet"},{"issue":"Suppl 2","key":"2245_CR19","doi-asserted-by":"publisher","first-page":"S728","DOI":"10.1016\/j.annonc.2023.09.2341","volume":"34","author":"D Keizer","year":"2023","unstructured":"Keizer D, Niemela E, Rozendaal YW, Karjalainen S, den Biezen E, van Brussel A, et al. 1252P Quantitative cell signaling activity profiling of solid tumors to support personalized treatment in the FINPROVE basket trial: presentation of skin tumor data. Ann Oncol. 2023;34(Suppl 2):S728. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2341.","journal-title":"Ann Oncol"},{"issue":"1","key":"2245_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13058-020-01314-6","volume":"22","author":"LI Madigan","year":"2020","unstructured":"Madigan LI, Dinh P, Graham JD. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women\u2014a literature review and proposed guidelines. Breast Cancer Res. 2020;22(1):77. https:\/\/doi.org\/10.1186\/s13058-020-01314-6.","journal-title":"Breast Cancer Res"},{"issue":"13","key":"2245_CR21","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39(13):1485\u2013505. https:\/\/doi.org\/10.1200\/JCO.20.03399.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2245_CR22","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1210\/en.2016-1928","volume":"158","author":"R Subramani","year":"2017","unstructured":"Subramani R, Nandy SB, Pedroza DA, Lakshmanaswamy R. Role of growth hormone in breast cancer. Endocrinology. 2017;158(6):1543\u201355. https:\/\/doi.org\/10.1210\/en.2016-1928.","journal-title":"Endocrinology"},{"issue":"2","key":"2245_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, ESMO Guidelines Committee, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(2):159\u201382.","journal-title":"Ann Oncol"},{"issue":"31","key":"2245_CR24","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1200\/JCO.2010.32.9615","volume":"29","author":"C Kim","year":"2011","unstructured":"Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, et al. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J Clin Oncol. 2011;29(31):4160\u20137.","journal-title":"J Clin Oncol"},{"key":"2245_CR25","doi-asserted-by":"publisher","unstructured":"Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat. 2007;105 Suppl 1:33\u201343. https:\/\/doi.org\/10.1007\/s10549-007-9701-x. Erratum in: Breast Cancer Res Treat. 2008;112(2):371.","DOI":"10.1007\/s10549-007-9701-x"},{"issue":"27","key":"2245_CR26","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817\u201326. https:\/\/doi.org\/10.1056\/NEJMoa041588.","journal-title":"N Engl J Med"},{"key":"2245_CR27","doi-asserted-by":"publisher","unstructured":"Cardoso F, van\u2019t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, MINDACT Investigators, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1602253. PMID:27557300.","DOI":"10.1056\/NEJMoa1602253"},{"key":"2245_CR28","doi-asserted-by":"publisher","unstructured":"Hartkopf AD, Grischke EM, Brucker SY. Endocrine-resistant breast cancer: mechanisms and treatment. Breast Care. 2020;15(4):347\u201354. https:\/\/doi.org\/10.1159\/000508675.","DOI":"10.1159\/000508675"},{"issue":"13","key":"2245_CR29","doi-asserted-by":"publisher","first-page":"9817","DOI":"10.1074\/jbc.M010840200","volume":"276","author":"RA Campbell","year":"2001","unstructured":"Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase\/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem. 2001;276(13):9817\u201324. https:\/\/doi.org\/10.1074\/jbc.M010840200.","journal-title":"J Biol Chem"},{"key":"2245_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41523-023-00533-2","volume":"9","author":"M Pegram","year":"2023","unstructured":"Pegram M, Jackisch C, Johnston SRD. Estrogen\/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive\/HER2-positive breast cancer. npj Breast Cancer. 2023;9:45.","journal-title":"npj Breast Cancer"},{"issue":"3","key":"2245_CR31","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10549-022-06637-w","volume":"196","author":"K Reinhardt","year":"2022","unstructured":"Reinhardt K, St\u00fcckrath K, Hartung C, Kaufhold S, Uleer C, Hanf V, Lantzsch T, Peschel S, John J, P\u00f6hler M, Bauer M, B\u00fcrrig FK, Weigert E, Buchmann J, Kantelhardt EJ, Thomssen C, Vetter M. PIK3CA-mutations in breast cancer. Breast Cancer Res Treat. 2022;196(3):483\u201393.","journal-title":"Breast Cancer Res Treat"},{"key":"2245_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"DC Koboldt","year":"2012","unstructured":"Koboldt DC, Fulton R, McLellan M, Schmidt H, Kalicki-Veizer J, McMichael J, Fulton L, Dooling D, Ding L, Mardis E, Wilson R. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370. https:\/\/doi.org\/10.1038\/nature11412.","journal-title":"Nature"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02245-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02245-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02245-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:46:56Z","timestamp":1774972016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02245-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2245"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02245-4","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study (NCT03283384) was conducted in accordance with the Declaration of Helsinki (October 2013) and approved by the Ethics Committee of the Leiden-The Hague-Delft hospitals in agreement with the Dutch law for medical research involving human subjects. All patients gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"G.J. Liefers: Institutional research support from Hologic.S.C. Linn: patents for PCT\/EP2022\/073958 and US2024\/0404625A1 pending; unrestricted educational fees to the institution (Endeavour Educational Program) from Daiichi Sankyo; and consultancy fees from Agendia and AstraZeneca paid to the institutionNon-financial interests: Scientific Advisory board member for CergentisInstitutional research support funding and\/or non-financial institutional benefits as (coordinating) PI from: Agendia, Agilent, Amgen, AstraZeneca, Eurocept-pharmaceuticals, Genentech, GSK, Merck, Novartis, Pfizer, Roche, and Sanofi. Institutional research support funding and\/or non-financial institutional benefits Immunomedics.J.R. Kroep: Consulting Fees (e.g., advisory boards) from Astra Zeneca, MSD, Novartis, Esai, GSK, all payed to the institution. Contracted research; Astra Zeneca, Novartis, Philips. Honorarium and Consulting Fees (e.g., advisory boards) from Daiichi Sankyo.Y. Wesseling-Rozendaal, D. Keizer, S. Vermeer and E. den Biezen are employees of InnoSIGN BV and own InnoSIGN shares and\/or options at the time of this project and preparation of this manuscript. Other authors declare no potential conflicts of interest. All authors declare consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}